Related Experiment Video
Updated: Apr 28, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.5K
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions
Tai Hato1, Lipika Goyal, Tim F Greten
1Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Hepatology (Baltimore, Md.)
|June 11, 2014
Summary
Immune checkpoint blockade shows promise for treating hepatocellular carcinoma (HCC). This review explores HCC immunology and the potential of immune checkpoint inhibitors for cancer therapy.
Area of Science:
- Oncology
- Immunology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is a significant malignancy with complex immune evasion mechanisms.
- Immune checkpoint blockade is an emerging therapeutic strategy for various cancers.
- Recent advances in tumor immunology offer new insights into cancer treatment.
Purpose of the Study:
- To review current knowledge on hepatocellular carcinoma (HCC) immunology.
- To discuss the potential of immune checkpoint blockade as a novel therapy for HCC.
- To provide basic, translational, and clinical perspectives on HCC immunotherapy.
Main Methods:
- Literature review of preclinical and clinical studies.
- Synthesis of current research on HCC immunology and immune evasion.
- Analysis of immune checkpoint blockade strategies in HCC.
Main Results:
- Modulating HCC immunogenicity shows potential therapeutic benefits.
- Understanding immune evasion mechanisms is crucial for effective treatment.
- Immune checkpoint blockade represents a promising avenue for HCC therapy.
Conclusions:
- Immune checkpoint blockade holds significant potential for treating hepatocellular carcinoma.
- Further research integrating basic, translational, and clinical findings is warranted.
- Targeting immune checkpoints could revolutionize HCC treatment strategies.
